Novo claims the defendants are steering patients toward compounded semaglutide that has not been approved by regulators; in ...

A new study in mice has found that muscle loss associated with weight loss from GLP-1 medications like Ozempic may not be as ...

The news comes days after Novo cut its full-year outlook due to rising competition from copycat compounders, and named a new ...